Please turn JavaScript on
tHEORetically Speaking - icon

tHEORetically Speaking -

follow.it gives you an easy way to subscribe to THEORetically Speaking -'s news feed! Click on Follow below and we deliver the updates you want via email, phone or you can read them here on the website on your own news page.

You can also unsubscribe anytime painlessly. You can even combine feeds from THEORetically Speaking - with other site's feeds!

Title: HealthEconomics.com - RWE, HEOR, and Market Access Content for Industry Professionals

Is this your feed? Claim it!

Publisher:  Unclaimed!
Message frequency:  0.4 / day

Message History

Written By Amy Sheide, Chief Data Officer, Ontada, and Wes Keller, Head of Product, Ontada

Speed in real‑world evidence (RWE) has become easier to demonstrate and harder to defend. Advances in AI have accelerated the extraction of insight from clinical data but have also raised the stakes. When evidence is reused across higher‑consequence decisions, spe...


Read full story

Eli Lilly has made a major strategic pivot back into infectious diseases by executing a trio of biotech acquisitions collectively valued at up to $3.8 billion. Funded by the massive financial success of its GLP-1 weight loss and diabetes portfolio, the drugmaker is acquiring Curevo, LimmaTech Biologics, and Vaccine Company (VaxCo). This aggressive...


Read full story

Exelixis, Inc. has announced a clinical development collaboration with Merck to support the upcoming STELLAR-316 phase 3 pivotal trial. Under the agreement, Merck will supply KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), its subcutaneous anti-PD-1 therapy, to be evaluated in combination with Exelixis’ investigational oral kinase ...


Read full story

Relay Therapeutics announced promising mid-stage clinical trial results for its drug prospect, zovegalisib, in treating vascular anomalies—a cluster of chronic conditions driven by PIK3CA gene mutations that cause abnormal blood vessel development. In a trial of 20 patients, the therapy demonstrated a 60% overall response rate across a 12-week reg...


Read full story

Neptune Medical’s Triton gastrointestinal robot successfully met its primary endpoints in a breakthrough first-in-human clinical trial. The study, which involved 50 adult patients in Poland, reported a 100% cecal intubation rate, meaning the robotic system successfully guided the endoscope through the entire colon in every procedure. Crucially, th...


Read full story